Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vitamin B6 shows promise for diabetes blood vessel health

NCT ID NCT06376240

Disease control Sponsor: Maastricht University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a form of vitamin B6 called pyridoxamine can improve the health of small blood vessels in people with type 2 diabetes. The researchers gave 40 participants either pyridoxamine or a placebo for a period, then switched treatments to compare effects. They measured blood vessel function in the eyes, kidneys, and skin to see if pyridoxamine could reduce the risk of diabetes-related complications like retinopathy, kidney disease, and nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Mar 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of type 2 diabetes, * Generalized microvascular dysfunction, i.e. * eGFR 30-60 mL/min/1.73m2, and/or * Microalbuminuria albumin-creatinine ratio 3-30 mg/mmol, and/or * Retinopathy (not proliferative), and/or * Neuropathy (any). Exclusion Criteria: * Uncontrolled diabetes (i.e., hypoglycaemia \>2 times/week and/or unstable HbA1c \>9%), * Use of \>12 Units long-acting insulin per day, * Use of short-acting insulin, * Intraocular pressure ≥30 mmHg, * History of glaucoma, * Diagnosis of proliferative diabetic retinopathy, * Diagnosis of diabetic macula edema, * Albumine-creatinine ratio \>30 mg/mmol, * eGFR \<30 mL/min/1.73m2, * Diagnosis of epilepsy, * Active cardiovascular disease, * Alcohol usage \>4 U/day, * Drugs abuse, * Use of systemic glucocorticosteroids, * Higher grade hypertension * Diagnosis of inflammatory disease, * Use of an investigational product within the previous month, * Unstable body weight, * Pregnancy or lactation, * Change in use of oral contraceptives or IUD, * Unwillingness to give up being a blood donor (or having donated blood) from 8 weeks prior to the start of the study to end of study, * Insufficient knowledge of the Dutch language, * Inability to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Microvascular function are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic kidney disease diabetic neuropathy diabetic retinopathy type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Microvascular function Nephropathy, diabetic Neuropathy, diabetic Retinopathy, diabetic Type 2 diabetes

Contacts and locations

Locations

  • Academic Hospital Maastricht

    Maastricht, 6229 HX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.